Paul Tudor Jones II acquired 622 Thousand Intra-Cellular Therapies shares worth $82 Million. That's 0.74% of their equity portfolio (13th largest holding). The first Intra-Cellular Therapies trade was made in Q1 2014. Since then Paul Tudor Jones II bought shares nine more times and sold shares on ten occasions. The stake costed the investor $77.1 Million, netting the investor a gain of 6.3% so far.